Roche says data in hepatitis treatment encouraging

ZURICH Thu Apr 19, 2012 11:06am IST

Related Topics

Stocks

   

ZURICH (Reuters) - Swiss drugmaker Roche said on Thursday initial data on a protease inhibitor, danoprevir, is encouraging against Hepatitis C.

"The high sustained viral response rates and encouraging safety data show danoprevir is potent and well-tolerated," Roche development head Hal Barron said in a statement.

"Roche's HCV portfolio includes multiple investigational drugs with different modes of action, allowing us to develop tailored treatments that aim to address the future needs of patients with chronic hepatitis C," Barron said.

(Reporting By Katharina Bart)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

EBOLA OUTBREAK

REUTERS SHOWCASE

Change Of Venue

Change Of Venue

Parks, playgrounds offer fresh air alternatives to gym workouts.  Full Article 

Antibiotics Quest

Antibiotics Quest

Extreme medicine: The search for new antibiotics.  Full Article 

Biotech Drugs

Biotech Drugs

'Plantibodies' drugs advance as big pharma stands aside.  Full Article 

Promising Vaccine

Promising Vaccine

Experimental chikungunya vaccine shows promise in human trial.  Full Article 

No Unanimity

No Unanimity

Even dentists differ on the best tooth-brushing method.  Full Article 

Importance Of Religion

Importance Of Religion

Religiosity associated with less depression in elderly: study.  Full Article 

Changing Demographic

Changing Demographic

From cradle to grave, Japan's Kewpie adapts menu to feed ageing nation.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage